BioLineRx Ltd. (TLV:BLRX)

BioLineRx Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	2.5	3.25	10.44	4.26	10.59	12.99
Short-Term Investments	14.85	17.63	9.13	38.74	40.5	44.15
Cash & Short-Term Investments	17.35	20.88	19.56	42.99	51.08	57.14
Cash Growth	-34.19%	6.72%	-54.50%	-15.83%	-10.59%	152.95%
Accounts Receivable	-	0.05	2.48	0.36	-	-
Other Receivables	1.89	0.41	1.39	0.35	0.72	0.14
Receivables	1.89	0.46	3.86	0.71	0.72	0.14
Inventory	2.16	2.15	3.15	1.95	-	-
Prepaid Expenses	0.18	0.2	0.44	1.05	0.2	0.13
Other Current Assets	-	-	0.09	0.48	-	-
Total Current Assets	21.58	23.68	27.1	47.18	52	57.4
Property, Plant & Equipment	0.87	0.86	1.35	1.89	2.5	2.28
Other Intangible Assets	16.35	16.37	10.45	14.85	21.89	21.7
Total Assets	38.8	40.91	38.91	63.93	76.38	81.39

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	4.91	3.49	5.58	10.87	6.97	5.57
Accrued Expenses	-	1.21	3.13	3.27	1.66	1.23
Current Portion of Long-Term Debt	4.48	4.48	4.48	3.15	1.54	2.76
Current Portion of Leases	0.25	0.23	0.52	0.53	0.43	0.17
Current Unearned Revenue	-	-	-	12.96	-	-
Other Current Liabilities	3.99	2.71	1.69	12.02	0.08	0
Total Current Liabilities	13.62	12.12	15.41	42.78	10.68	9.72
Long-Term Debt	3.36	4.46	8.96	6.63	8.63	-
Long-Term Leases	0.98	0.98	1.08	1.29	1.73	1.73
Other Long-Term Liabilities	-	-	-	-	4.51	1.86
Total Liabilities	17.96	17.56	25.45	50.7	25.54	13.3

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	73.43	73.43	38.1	31.36	27.1	21.07
Additional Paid-In Capital	327.58	327.58	353.69	355.48	338.98	339.35
Retained Earnings	-402.6	-401	-399.83	-390.61	-329.99	-305.04
Comprehensive Income & Other	18.26	18.19	21.5	16.99	14.76	12.72
Total Common Equity	16.67	18.2	13.46	13.22	50.84	68.09
Minority Interest	4.16	5.15	-	-	-	-
Shareholders' Equity	20.84	23.35	13.46	13.22	50.84	68.09
Total Liabilities & Equity	38.8	40.91	38.91	63.93	76.38	81.39

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	9.07	10.15	15.04	11.59	12.32	4.65
Net Cash (Debt)	8.28	10.73	4.52	31.4	38.76	52.48
Net Cash Growth	-34.40%	137.20%	-85.60%	-18.98%	-26.15%	252.17%
Net Cash Per Share	0.00	0.00	0.00	0.03	0.05	0.08
Filing Date Shares Outstanding	2,611	2,611	2,233	1,087	922.96	715.16
Total Common Shares Outstanding	2,611	2,611	1,337	1,087	922.96	715.16
Working Capital	7.96	11.56	11.7	4.4	41.32	47.69
Book Value Per Share	0.01	0.01	0.01	0.01	0.06	0.10
Tangible Book Value	0.33	1.83	3.01	-1.63	28.96	46.38
Tangible Book Value Per Share	0.00	0.00	0.00	-0.00	0.03	0.06
Machinery	-	2.11	2.29	2.93	2.81	2.66
Leasehold Improvements	-	2.04	2.04	2.04	2.04	2.03

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 3, 2026

Data Sources Report a data error